Development of 18F-Labeled Picolinamide Probes for PET Imaging of Malignant Melanoma
摘要:
Melanoma is an aggressive skin cancer with worldwide increasing incidence. Development of positron emission tomography (PET) probes for early detection of melanoma is critical for improving the survival rate of melanoma patients. In this research, F-18-picolinamide-based PET probes were prepared by direct radiofluorination of the bromopicolinamide precursors using no-carrier-added F-18-fluoride. The resulting probes, F-18-1, F-18-2 and F-18-3, were then evaluated in vivo by small animal PET imaging and biodistribution studies in C57BL/6 mice bearing B16F10 murine melanoma tumors. Noninvasive small animal PET studies demonstrated excellent tumor imaging contrasts for all probes, while F-18-2 showed higher tumor to muscle ratios than F-18-1 and F-18-3. Furthermore, F-18-2 demonstrated good in vivo stability as evidenced by the low bone uptake in biodistribution studies. Collectively, these findings suggest F-18-2 as a highly promising PET probe for translation into clinical detection of melanoma.
Synthesis and Preclinical Evaluation of <sup>18</sup>F-PEG<sub>3</sub>-FPN for the Detection of Metastatic Pigmented Melanoma
作者:Xiaodong Xu、Lujie Yuan、Lianglan Yin、Yaqun Jiang、Yongkang Gai、Qingyao Liu、Yichun Wang、Yongxue Zhang、Xiaoli Lan
DOI:10.1021/acs.molpharmaceut.7b00607
日期:2017.11.6
Although F-18-5-fluoro-N-(2-[diethylamino]-ethyl)picolinamide (F-18-5-FPN) is considered a promising radiopharmaceutical for PET imaging of melanoma, it accumulates at high concentrations in the liver. The aim in this research was to optimize the structure of F-18-5-FPN with triethylene glycol to reduce liver uptake as well as improve pharmacokinetics, and to evaluate its performance in detection of melanoma liver and lung metastases. F-18-PEG(3)-FPN was successfully prepared with a high radiolabeling yield (44.68% +/- 5.99%) and radiochemical purity (> 99%). The uptake of F-18-PEG3-FPN by pigmented B16F10 melanoma cells was significantly higher than that by amelanotic melanoma A375 cells. The binding to B16F10 cells could be blocked by excess F-19-PEG(3)-FPN. On small animal PET images, B16F10 tumors, but not A375 tumors, were clearly delineated after F-18-PEG(3)-FPN injection. More importantly, F-18-PEG(3)-FPN uptake by liver (2.27 +/- 0.45 and 1.74 +/- 0.35% ID/g, at 1 and 2 h) was significantly lower than that of F-18-5-FPN, and the lesions in lung and liver could be clearly detected by F-18-PEG3-FPN PET imaging in mouse models of pulmonary or hepatic metastases. Overall, we successfully synthesized F-18-PEG(3)-FPN, which has higher labeling efficacy and better in vivo pharmacokinetics along with lower liver uptake compared to F-18-5-FPN. This suggests F-18-PEG(3)-FPN as a candidate for pigmented melanoma liver and lung metastasis detection.
METHODS OF PARKINSONS DISEASE DIAGNOSIS AND MONITORING TREATMENT
申请人:The Board of Trustees of the Leland Stanford Junior University
公开号:US20150023877A1
公开(公告)日:2015-01-22
Embodiments of the present disclosure provide for methods of using labeled probes, methods of diagnosing Parkinson's disease and related biological events, methods of using labeled probes for monitoring and/or assessing Parkinson's disease treatment, methods of using labeled probes for diagnosing, monitoring, and/or assessing diseases with aberrant melanin-expression, and the like.
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
作者:Jason B. Cross、Jing Zhang、Qingyi Yang、Michael F. Mesleh、Jan Antoinette C. Romero、Bin Wang、Doug Bevan、Katherine M. Poutsiaka、Felix Epie、Terence Moy、Anu Daniel、Joseph Shotwell、Brian Chamberlain、Nicole Carter、Ole Andersen、John Barker、M. Dominic Ryan、Chester A. Metcalf、Jared Silverman、Kien Nguyen、Blaise Lippa、Roland E. Dolle
DOI:10.1021/acsmedchemlett.5b00368
日期:2016.4.14
attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class of pyrazolopyridone inhibitors was discovered by optimizing a fragment screening hit scaffold using structure guided design. These inhibitors show potent Gram-positive antibacterial activity and low resistance incidence against clinically important pathogens.
Melanoma is an aggressive skin cancer with worldwide increasing incidence. Development of positron emission tomography (PET) probes for early detection of melanoma is critical for improving the survival rate of melanoma patients. In this research, F-18-picolinamide-based PET probes were prepared by direct radiofluorination of the bromopicolinamide precursors using no-carrier-added F-18-fluoride. The resulting probes, F-18-1, F-18-2 and F-18-3, were then evaluated in vivo by small animal PET imaging and biodistribution studies in C57BL/6 mice bearing B16F10 murine melanoma tumors. Noninvasive small animal PET studies demonstrated excellent tumor imaging contrasts for all probes, while F-18-2 showed higher tumor to muscle ratios than F-18-1 and F-18-3. Furthermore, F-18-2 demonstrated good in vivo stability as evidenced by the low bone uptake in biodistribution studies. Collectively, these findings suggest F-18-2 as a highly promising PET probe for translation into clinical detection of melanoma.